# US 2023/0181698 A1 · Methods and compositions for rna-guided treatment of hiv infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0181698 A1
- Document ID: US20230181698A1
- Status: Published application
- Kind: A1
- Application number: 17/832,457
- Filed: 2022-06-03
- Published: 2023-06-15
- Earliest claimed: 2013-08-29
- Assignees: Temple University of the Commonwealth System of Higher Education
- Applicants: Temple University-of The Commonwealth System of Higher Education
- Inventors: Kamel Khalili; Wenhui Hu
- Web page: https://patentgrep.com/patent/US20230181698A1

## CPC

- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/30: Special therapeutic applications
- C12N 2740/16063: by chemical treatment
- C12Y 301/21: Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A method of preventing transmission of a retrovirus from a mother to her offspring, by administering to the mother a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and the two or more different multiplex gRNAs, wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-I proviral genome, eradicating the HIV-I proviral DNA from the host cell, and preventing transmission of the proviral DNA to the offspring.

## Claims

### Claim 1

A method of excising part or all of a retroviral sequence from a genome of a cell, the method comprising contacting the cell with:
a. a CRISPR-associated endonuclease or a nucleic acid encoding the CRISPR-associated endonuclease;
b. a first guide RNA (gRNA) or a nucleic acid encoding the first gRNA, the first gRNA being complementary to a first target nucleic acid site within the retroviral sequence; and
c. a second gRNA or nucleic acid encoding the second gRNA, the second gRNA being complementary to a second target nucleic acid site within the retroviral sequence.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first target nucleic acid site is within section U3, R, or U5 region of a 5′ long terminal repeat (LTR).

### Claim 3 (depends on 1)

The method of claim 1, wherein the first target nucleic acid site is within section U3, R, or U5 region of a 3′ LTR.

### Claim 4 (depends on 1)

The method of claim 1, wherein the second target nucleic acid site is within section U3, R, or U5 region of a 5′ long terminal repeat (LTR).

### Claim 5 (depends on 1)

The method of claim 1, wherein the second target nucleic acid site is within section U3, R, or U5 region of a 3′ LTR.

### Claim 6

A method of excising part or all of a retroviral sequence from a genome of a cell, the method comprising contacting the cell with:
a. a CRISPR-associated endonuclease or a nucleic acid encoding the CRISPR-associated endonuclease; and
b. at least one guide RNA (gRNA) or a nucleic acid encoding the at least one gRNA, one or more of the at least one gRNA being complementary to a first target nucleic acid site within a retroviral sequence and one or more of the at least one gRNA being complementary to a second target nucleic acid site within the retroviral sequence.

### Claim 7 (depends on 6)

The method of claim 6, wherein the first target nucleic acid site is within section U3, R, or U5 region of a 5′ long terminal repeat (LTR).

### Claim 8 (depends on 6)

The method of claim 6, wherein the first target nucleic acid site is within section U3, R, or U5 region of a 3′ LTR.

### Claim 9 (depends on 6)

The method of claim 6, wherein the second target nucleic acid site is within section U3, R, or U5 region of a 5′ long terminal repeat (LTR).

### Claim 10 (depends on 6)

The method of claim 6, wherein the second target nucleic acid site is within section U3, R, or U5 region of a 3′ LTR.

### Claim 11

A composition:
a. a CRISPR-associated endonuclease or a nucleic acid encoding the CRISPR-associated endonuclease;
b. a first guide RNA (gRNA) or a nucleic acid encoding the first gRNA, the first gRNA being complementary to a first target nucleic acid site within a retroviral sequence;
c. a second gRNA or nucleic acid encoding the second gRNA, the second gRNA being complementary to a second target nucleic acid site within the retroviral sequence; and
d. an excipient.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the first target nucleic acid site is within section U3, R, or U5 region of a 5′ long terminal repeat (LTR).

### Claim 13 (depends on 11)

The composition of claim 11, wherein the first target nucleic acid site is within section U3, R, or U5 region of a 3′ LTR.

### Claim 14 (depends on 11)

The composition of claim 11, wherein the second target nucleic acid site is within section U3, R, or U5 region of a 5′ long terminal repeat (LTR).

### Claim 15 (depends on 11)

The composition of claim 11, wherein the second target nucleic acid site is within section U3, R, or U5 region of a 3′ LTR.

### Claim 16 (depends on 11)

The composition of claim 11, wherein the nucleic acid sequence encoding the CRISPR-associated endonuclease, the nucleic acid sequence encoding the first gRNA, and the nucleic acid sequence encoding the second gRNA are in a same expression vector.

### Claim 17 (depends on 11)

The composition of claim 11, wherein the nucleic acid sequence encoding the CRISPR-associated endonuclease, the nucleic acid sequence encoding the first gRNA, and the nucleic acid sequence encoding the second gRNA are in different expression vectors.
